Urology
Volume 76, Issue 2 , Pages 430-434 , August 2010

Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy

  • Michael M. Vickers

      Affiliations

    • Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada
    • ,
  • Toni K. Choueiri

      Affiliations

    • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Miranda Rogers

      Affiliations

    • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Andrew Percy

      Affiliations

    • Department of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    • ,
  • Daygen Finch

      Affiliations

    • Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • Ivan Zama

      Affiliations

    • Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
    • ,
  • Tina Cheng

      Affiliations

    • Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada
    • ,
  • Scott North

      Affiliations

    • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Jennifer J. Knox

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Christian Kollmannsberger

      Affiliations

    • Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
    • ,
  • David F. McDermott

      Affiliations

    • Department of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    • ,
  • Brian I. Rini

      Affiliations

    • Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
    • ,
  • Daniel Y. Heng

      Affiliations

    • Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada
    • Corresponding Author InformationReprint requests: Daniel Y. C. Heng, M.D., M.P.H., F.R.C.P.C., Department of Oncology, Tom Baker Cancer Center, University of Calgary, 1331–29th Street NW, Calgary, Alberta, Canada T2N 4N2

Received 30 November 2009 ,Accepted 5 December 2009.

References 

  1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  2. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111
  3. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422–5428
  4. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281
  5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  6. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008;372:449–456
  7. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29–34
  8. Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61–67
  9. Shepard DR, Rini BI, Garcia JA. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [ASCO Annual Meeting Proceedings]. J Clin Oncol. 2008;26(suppl 15):5123
  10. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4462–4468
  11. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3743–3748
  12. Drabkin HA, Figlin RA, Stadler WM, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment [ASCO Annual Meeting Proceedings]. J Clin Oncol. 2007;25(suppl):5041
  13. Wood L, Bukowski RM, Dreicer R, et al. Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy [ASCO Annual Meeting Proceedings]. J Clin Oncol. 2008;26(suppl 15):16067
  14. Heng DY, Xie W, Regan M, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–5799http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2008.21.4809
  15. Dutcher JP, De Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26:202–209
  16. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127–131
  17. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2008;27:235–241
  18. Escudier B. Signaling inhibitors in metastatic renal cell carcinoma. Cancer J. 2008;14:325–329
  19. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179:81–86

 Conflicts of interests: Toni K. Choueiri, Honoraria: Novartis, Abbott, GSK, Genentech, Consultant/Advisory role: Bayer, Onyx, Pfizer; Scott North, Honoraria: Pfizer, Bayer, Wyeth; Brian I. Rini, Honoraria: Wyeth, Pfizer, Genentech, Bayer, Onyx, Consultant/Advisory role: Pfizer, Onyx, Wyeth, Bayer, Genentech; Daniel Y. Heng, Honoraria: Bayer, Wyeth, Pfizer. Michael M. Vickers, Miranda Rogers, Andrew Percy, Daygen Finch, Ivan Zama, Tina Cheng, Jennifer J. Knox, Christian Kollmannsberger, and David F. McDermott had no conflicts of interest.

PII: S0090-4295(09)03118-5

doi: 10.1016/j.urology.2009.12.031

Urology
Volume 76, Issue 2 , Pages 430-434 , August 2010

Article Tools

* Image Usage & Resolution